Al Efishat Mohammad, Allen Peter J
Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA; Department of Surgery, Johns Hopkins Hospital, 600 N Wolfe Street, Baltimore, MD 21287, USA.
Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Surg Oncol Clin N Am. 2016 Apr;25(2):351-61. doi: 10.1016/j.soc.2015.11.006.
Management of cystic neoplasms of the pancreas is challenging as it relies on radiologic and cyst fluid markers to discriminate between benign and pre-cancerous lesions, however their ability to predict malignancy is limited. While asymptomatic serous cystadenomas can be managed conservatively, mucinous cystic neoplasms and intraductal papillary mucinous neoplasms are more difficult to manage. A selective approach, based on the preoperative likelihood of high-grade dysplasia or invasive disease, is the standard of care. Research is focusing on the development of pre-operative markers for identifying high risk lesions, which will spare patients with low-risk or benign lesions the risks of pancreatectomy.
胰腺囊性肿瘤的管理具有挑战性,因为它依赖于放射学和囊液标志物来区分良性和癌前病变,然而它们预测恶性肿瘤的能力有限。虽然无症状的浆液性囊腺瘤可以保守治疗,但黏液性囊性肿瘤和导管内乳头状黏液性肿瘤则更难处理。基于高级别异型增生或浸润性疾病的术前可能性的选择性方法是标准治疗方案。研究正集中于开发用于识别高风险病变的术前标志物,这将使低风险或良性病变的患者免受胰腺切除术的风险。